Bayer’s Factor XIa inhibitor reduces repeat stroke risk by 26% in pivotal trial
Bayer’s investigational, once-daily, oral Factor XIa inhibitor asundexian reduced the risk of recurrent ischemic stroke by 26% in a pivotal…
Cardiovascular
-
-
JPM26: Eli Lilly highlights Lp(a) drugs as cardiovascular growth focus
At the 44th Annual JP Morgan Healthcare conference 2026, Eli Lilly highlighted lepodisiran and muvalaplin as the key drugs in…
-
BioAge’s NLRP3 inhibitor shows potential to reduce cardiovascular risk
BioAge’s NLRP3 inhibitor has shown potential to reduce high-sensitivity C-reactive protein (hsCRP), a key marker of cardiovascular risk, in an…
-
BMS and Johnson & Johnson terminate Phase III ACS trial due to likely failure
Editor’s note: This article has been updated to clarify that the collaboration was with Johnson & Johnson, not AstraZeneca as…
-
AHA 2025: satralizumab shows benefit in immune-driven pulmonary arterial hypertension
At the 2025 American Heart Association (AHA) Scientific Sessions in New Orleans, investigators from Japan presented results from the SATISFY-JP…
-
Long-term benefit of Amgen’s Repatha in reducing MACE shown in Phase III trial
Amgen's Repatha (evolocumab) has shown benefit in a long-term study in reducing cardiovascular incidents in patients without a prior history…
-
Podcast: key trials and trends from ESC Congress 2025
Eyes in the pharma and medtech industries are directed to the European Society of Cardiology (ESC) Congress every year to…
-
MSD’s oral PCSK9 scores Phase III hat-trick
MSD’s oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor has succeeded in a third Phase III trial in patients with…
-
ESC 2025: Cytokinetics’ oHCM drug outperforms SoC beta blockers
Cytokinetics’ aficamten outperformed standard of care (SoC) in a Phase III trial in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM),…
-
ESC 2025: post-hoc SURMOUNT-5 data affirms tirzepatide’s lead in CVD risk reduction
At the European Society of Cardiology (ESC) Congress 2025, findings from a post-hoc analysis of the SURMOUNT-5 trial (NCT05822830) were…
